⌕
Candel Therapeutics · CADL · Nasdaq
Tenet 45 · Mixed
Compare
$5.81−6.29%At closeTenet 45 · Mixed
$5.81−0.39 (−6.29%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Candel Therapeutics (CADL) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business engineChoppy: revenue history is too short to read a growth trend (through FY22), net margin −15035.2%. Worth your attention in FY25: Share count (+180.6%) and Capex step-up ($587.0K). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲30.8%
−38.2
FY21→FY25CAGR —
Free cash flow ($M)▼43.9%
−38.9
capex stepped upCAGR —
Diluted EPS▲58.6%
−0.72
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+180.6%

18.9mn → 53.0mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex step-up
$587.0K

▲3569% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−30.5R&D−17.8SG&A−48.3Op income10.1Tax & other−38.2Net income

Margin trend · direction beats level Gross Operating Net
1007550250%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.6843, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.0125.0125.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.0125.0125.0——
Research & development
56,256.030,496.019,314.024,506.020,787.015,178.0▲57.9%+19.1%
Selling, general & admin
25,507.017,770.014,057.013,885.014,060.010,673.0▲26.4%+13.6%
Total operating expenses
81,763.048,266.033,371.038,391.034,847.025,851.0▲44.6%+16.9%
Operating incomefeeds ROC rank
−81,763.0−48,266.0−33,371.0−38,391.0−34,722.0−25,726.0▼44.6%—
Other income, net
−17,372.010,084.0−21,806.0452.015,928.0−10,398.0——
Pretax income
−99,135.0−38,182.0−55,177.0−37,939.0−18,794.0−36,124.0▲30.8%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−99,135.0−38,182.0−55,177.0−37,939.0−18,794.0−36,124.0▲30.8%—
Per share
Diluted EPSbuyback-sensitive
−1.49−0.72−1.74−1.31−0.65−1.91▲58.6%—
Diluted shares (mn)
77.3952.9631.6828.9428.8218.87▲67.2%+29.4%
Margins
Gross margin
————100.0%100.0%——
Operating margin
————−27777.6%−20580.8%——
Net margin2nd pct in Healthcare
————−15035.2%−28899.2%——
† TTM = trailing four quarters through 2026-09-30.
FY20 – FY20 · 1 more year
Unlock the full history →
1 more year of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-12 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.